Coronary stent thrombosis
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Associate Editors-In-Chief: William J. Gibson, Harvard Medical School; Varun Kumar, M.B.B.S.; Lakshmi Gopalakrishnan, M.B.B.S.
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Introduction
Definition
Overview | Issues with interpreting data | Definition based on timing of ST | Definition based on certainty of ST
Incidence
Relation to Bare Metal Stents | Relation to Drug Eluting Stents | Sirolimus eluting stent vs Paclitaxel eluting stent | Relation to antiplatelet medications
Mechanism and Pathophysiology
Overview | Mechanisms and pathophysiology | Clinical trial data
Etiology
Predictors of stent thrombosis | Risk factors for early ST | Risk factors for late ST | Risk factors for very late ST
Premature discontinuation of antiplatelet therapy
Incidence | Predictors | Risk associated with premature discontinuation | Risk associated with late discontinuation | Duration of therapy | Failure of therapy | Prevention of premature discontinuation
Treatment
Prognosis
Recurrence of stent thrombosis | Myocardial infarction